From: National Marrow Donor Program
To: Julie Manley
Subject: [Test]:%%First Name%%, Learn about Medicare Drug Reimbursement Updates
Date: Friday, April 12, 2019 3:54:36 PM

Having trouble viewing this email? View as a web page.

BE THE MATCH REIMBURSEMENT Update

Forward Subscribe

NMDP Comments on CMS Proposed Rules

The Health and Public Policy team is committed to patient access to cellular therapies and comments on CMS proposed rules when they would have an impact on our patient population. Read our comment letters below to learn about our advocacy to process access to care for patients.

Medicare Drug Coverage

- The NMDP submitted a comment letter to the proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-Of-Pocket Expenses," detailing our concerns regarding applying utilization management tools, prior authorization and step therapy, to protected class drugs, which include chemotherapy and immunosuppressive drugs, as well as other exclusions. Read our comment letter.

Medicaid Network Adequacy

- The NMDP submitted a comment letter to the proposed rule, "Medicaid Program; Medicaid and Children's Health Insurance Program (CHIP) Managed Care," detailing our concerns regarding access barriers for patients with proposed changes to network adequacy requirements and standards regarding "specialist" definitions. Read our comment letter.

Join Our Day of Action

Our volunteers are visiting Capitol Hill to meet with their Members of Congress to advocate for full funding of the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory. **Full funding means life-saving breakthroughs** - We can advance new and innovative methods of providing the best possible transplant to every patient in need, regardless of ethnic ancestry, socioeconomic status, age, or any other individually defining characteristic.This is an **incredible** time in the world of cellular therapy, as new innovations are leading us to the cusp of major breakthroughs. **But our work – and that of Congress – is not done.** Even today, every three minutes someone will be diagnosed with a blood cancer. **Join our day of action** by sending an email and tweeting your Member of Congress now.

AMPLIFY THE VOICES OF PATIENTS IN NEED. CONTACT YOUR MEMBER OF CONGRESS.

Coming Up: Transplantation and Cellular Therapy Meetings (TCT)

We hope to see you at TCT, the joint meeting of ASBMT and CIBMTR (formerly the BMT Tandem Meetings) in Houston, TX, February 20-24.
The Health and Public Policy team will be presenting:

- **Medicare Updates, Case Studies & Hot Topics**– This session will presented at the Administrative Director Conference and will provide details on: Medicare coverage for HCT, reporting donor expenses, ways to impact reimbursement, and how to get involved in advocacy. Co-presented by Rachel Glissmann, Research and Policy Liaison on the Health and Public Policy team, and Valerie Rinkle of Nimitt Consulting.
- **Utilization of Fertility Preservation Services By Patients Aged 18-40 Prior to Hematopietic Cell Transplantation** - This presentation explores commercially insured and covered fertility preservation utilization among HCT recipients. Presented by Michelle SanCartier, Health Policy Analyst on the Health and Public Policy Team.

We'll also be holding a meeting with one of our board advisory group, the Advisory Group on Barriers to Transplant, where we'll discuss emerging cellular therapies, CAR-T

coding and billing issues, and set goals for work in the upcoming year, including patient care coordination and financial toxicity. This group is currently chaired by Julie Walz (Humana) and Dr. Gunjan Shah (Memorial Sloan Kettering Cancer Center). We look forward to sharing the results with the provider community in March.It will be an exciting meeting! We hope to see you there.

LEARN MORE ABOUT THE TRANSPLANTATION AND CELLULAR THERAPY MEETINGS (TCT)

New CAR-T Resources

The ASBMT released updated resources on CAR-T billing and coding. Find the new resources for 2019 here.

Have Questions?

We are available to answer questions and offer support.

bethematch.org/advocacy

Feedback

@BTMPublicPolicy

Be part of our Twitter community. Follow us for up-to-date information on legislation and health policy.

Follow Us

This e-mail is sent only to individuals who have requested to receive E-communications from NMDP. If this email was forwarded to you, we invite you to subscribe. If you would like to stop receiving education notices and our clinical e-newsletter, please unsubscribe.

Copyright © 2018 National Marrow Donor Program®

This email was sent by: **National Marrow Donor Program**
500 N 5th St Minneapolis, MN, 55401, US | 1 (800) MARROW-2